Scipher Medicine

Scipher Medicine™ Announces Publication of Clinical Study Validating PrismRA®, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis

Retrieved on: 
Tuesday, July 28, 2020
Data management, Biotechnology, Technology, Health, Pharmaceutical, Research, Software, Nanotechnology, Genetics, Science, Clinical trials, Medical specialties, Clinical medicine, Medicine, RTT, Rheumatology, Immunosuppressants, Autoimmune diseases, Disease-modifying antirheumatic drug, Rheumatoid arthritis, TNF inhibitor, Arthritis, Methotrexate, PrismRA®, Scipher Medicine

The publication titled Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients was published in Network and Systems Medicine .

Key Points: 
  • The publication titled Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients was published in Network and Systems Medicine .
  • PrismRA uses whole blood gene expression data to identify if a patients molecular disease biology is suited to TNFi therapy.
  • About 90% of patients with rheumatoid arthritis are prescribed TNFi therapy after failing disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate.
  • However, a majority of patients fail to achieve a clinically meaningful change, said Dr. Slava Akmaev, Chief Technology Officer of Scipher Medicine.

Scipher Medicine Announces Investment by Optum Ventures Focused on Improving Patient Outcomes

Retrieved on: 
Wednesday, February 19, 2020
Data management, Health, Technology, Software, Pharmaceutical, Biotechnology, Health sciences, Health, Articles, Optum, UnitedHealth Group, Molecular diagnostics, Therapy, Scipher Medicine, Optum Ventures

Under the terms of the agreement, Optum Ventures has made an equity investment in Scipher Medicine to accelerate the companys efforts to improve patient outcomes by using molecular diagnostics to identify the best therapy prior to treatment initiation.

Key Points: 
  • Under the terms of the agreement, Optum Ventures has made an equity investment in Scipher Medicine to accelerate the companys efforts to improve patient outcomes by using molecular diagnostics to identify the best therapy prior to treatment initiation.
  • Outcomes can be improved dramatically when patients are prescribed the right therapy from day one, said Alif Saleh, CEO of Scipher Medicine.
  • The investment by Optum Ventures represents a second close in Scipher Medicines previously announced Series B round.
  • Scipher Medicine is privately held, headquartered in Waltham, Massachusetts, and backed by Khosla Ventures, Northpond Ventures and UnitedHealth Group.